摘要
目的探讨紫杉醇脂质体联合顺铂化疗对中晚期宫颈癌患者T淋巴细胞亚群、肿瘤标志物的影响。方法根据治疗方式的不同将83例中晚期宫颈癌患者分为对照组(n=41)和观察组(n=42),对照组患者给予紫杉醇^(+)顺铂化疗,观察组患者给予紫杉醇脂质体^(+)顺铂化疗。比较两组患者T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+),计算CD4^(+)/CD8^(+))水平、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、CD105]水平和不良反应发生情况。结果治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,且观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CYFRA21-1、CD105水平均低于本组治疗前,且观察组患者CYFRA21-1、CD105水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为42.86%,低于对照组患者的68.29%,差异有统计学意义(P﹤0.05)。结论紫杉醇脂质体联合顺铂化疗可有效改善中晚期宫颈癌患者的T淋巴细胞亚群水平,降低CYFRA21-1、CD105水平,同时不良反应较少。
Objective To investigate the effect of paclitaxel liposome combined with cisplatin chemotherapy on T lymphocyte subsets and tumor markers in patients with advanced cervical cancer.Method According to different treat-ment methods,83 patients with advanced cervical cancer were divided into control group(n=41)and observation group(n=42).The control group was given paclitaxel^(+)cisplatin chemotherapy,and the observation group was given paclitaxel liposome^(+)cisplatin chemotherapy.The levels of T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),tumor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),CD105]and the occurrence of adverse reactions were compared between the two groups of patients.Result After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before treatment,and the levels of CD8^(+)were lower than those before treatment,and the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CYFRA21-1 and CD105 in the two groups were lower than those before treatment,and the levels of CYFRA21-1 and CD105 in the observation group were lower than those in the control group,with statistical significance(P<0.05).The to-tal incidence of adverse reactions in the observation group was 42.86%,which was lower than 68.29%in the control group,and the difference was statistically significant(P<0.05).Conclusion Paclitaxel liposome combined with cisplatin chemotherapy can effectively improve the level of T lymphocyte subsets in patients with advanced cervical cancer,reduce the levels of CYFRA21-1 and CD105,and have fewer adverse reactions.
作者
袁永兴
高建建
逯蕾
YUAN Yongxing;GAO Jianjian;LU Lei(Department of Gynecology,Xi’an International Medical Center Hospital,Xi’an 710100,Shaanxi,China)
出处
《癌症进展》
2022年第9期952-955,共4页
Oncology Progress
